SECTRAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SECTRAL (SECTRAL).
Selective beta-1 adrenergic receptor antagonist; negative chronotropic and inotropic effects, reduces cardiac output, decreases renin release.
| Metabolism | Hepatic metabolism via CYP2D6; minor pathways involve conjugation. |
| Excretion | Renal: ~30-40% unchanged; biliary/fecal: ~20-30% as metabolites and parent compound; total renal clearance accounts for 50-70% of elimination. |
| Half-life | Terminal elimination half-life: 8-13 hours; clinically, this supports once-daily dosing, but steady-state is achieved within 2-3 days. |
| Protein binding | ~25-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: 1.1-2.6 L/kg; indicates extensive distribution into extravascular tissues. |
| Bioavailability | Oral: 40-70% (average ~50%) due to first-pass metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral: 1-2 hours for beta-blockade effect on heart rate; maximal effect in 2-4 hours. |
| Duration of Action | Duration of beta-blockade: 12-24 hours; clinical effect persists for 24 hours with once-daily dosing, supporting single daily administration. |
Adult: 200–400 mg orally once daily, initially; may increase to 400–800 mg daily in divided doses (e.g., 200 mg twice daily). Maximum 800 mg/day. Route: Oral.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30–50 mL/min: reduce dose by 25%; GFR 10–29 mL/min: reduce dose by 50%; GFR <10 mL/min: administer 50% of normal dose every 48 hours or 25% every 24 hours. |
| Liver impairment | No specific dosing guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment; consider dose reduction due to reduced clearance. |
| Pediatric use | Not FDA-approved for pediatric use. Limited data: 8–10 mg/kg/day orally in 1–2 divided doses; maximum 400 mg/day. |
| Geriatric use | Start at 200 mg once daily. Increase cautiously due to age-related decline in renal and hepatic function; monitor for bradycardia and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SECTRAL (SECTRAL).
| Breastfeeding | Acebutolol and its active metabolite diacetolol are excreted into breast milk. M/P ratio is approximately 7 for acebutolol and 12 for diacetolol. Infant serum levels may be clinically significant, potentially causing bradycardia and hypotension; monitor infant for adverse effects. |
| Teratogenic Risk | First trimester: Limited data; beta-blockers may cause fetal bradycardia, growth restriction, and hypoglycemia. Second and third trimesters: Continued risk of fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia; use only if benefit outweighs risk. |
■ FDA Black Box Warning
Abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease.
| Serious Effects |
Cardiogenic shock, sinus bradycardia, heart block greater than first degree, severe heart failure (NYHA class IV), hypersensitivity to acebutolol or other beta-blockers.
| Precautions | Cardiogenic shock, sinus bradycardia, heart block greater than first degree, heart failure exacerbation, bronchospasm in asthma/COPD, masking of hypoglycemia, peripheral vascular disease, abrupt withdrawal. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal heart rate, blood pressure, and signs of heart failure. Fetal monitoring including heart rate and growth via ultrasound. Neonatal monitoring for bradycardia, hypoglycemia, and respiratory depression after delivery. |
| Fertility Effects | No specific studies; beta-blockers may reduce sperm motility and function in males, and may affect ovulation in females, but clinical significance is unclear. |